New data from HeartBeam has highlighted the company’s namesake electrocardiogram’s (ECG’s) potential in identifying heart attacks in patients experiencing chest pain, advancing evidence to support the company’s planned indication expansion into heart attack detection.
HeartBeam’s ECG system comes in the form of a credit card-sized device that patients hold to their chest to record the heart’s electrical signals. Known as vector electrocardiography (VECG), the California-based company’s technology works by gathering 3D signals of the heart and converting them into a 12-lead ECG. The US Food and Drug Administration (FDA) cleared the device in December 2025 for at-home arrhythmia assessment.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Published in the June edition of JACC: Advances, HeartBeam’s proof-of-concept study evaluated whether a risk prediction algorithm could close the ‘symptom to door’ gap by combining an ECG reading from HeartBeam’s device, a patient’s pre-existing cardiovascular risk factors, and a structured symptom assessment into a single algorithmicised risk score.
Evaluating 184 patients, when using a single ECG reading from HeartBeam’s device combined with patient risk factors and symptoms, the risk score achieved an 86.5% area under curve (AUC) – a statistical measure of diagnostic accuracy for heart attack risk prediction models or artificial intelligence (AI)-based screening tools.
Meanwhile, when a symptom-free baseline ECG previously recorded on the same HeartBeam device was available for comparison, AUC increased to 92.9%. HeartBeam stated that the data represented an “important finding”, given that physicians evaluating an ECG from the company’s system will always have the patient’s baseline ECG for comparison, potentially increasing the ability to detect a heart attack.
The company’s stock, listed on the Nasdaq exchange, is estimated to rise by 2.74% at market open today, based on the pre-market at 5.30am ET.
Commenting on the study outcomes, HeartBeam CEO, Robert Eno, said: “This study is an important piece of the scientific foundation we are building toward heart attack detection as a future indication for the HeartBeam System. The results demonstrate that a clinical-grade ECG provided by our device, combined with a patient’s clinical history and symptoms, can deliver risk assessment comparable to physician evaluation with a traditional 12-lead ECG.
“In practical terms, a patient experiencing chest pain could use the HeartBeam system at home, reducing hesitation to seek medical help, reducing time to intervention and potentially improving outcomes in the event of a heart attack.”
Alongside the pilot study data, HeartBeam initiated enrolment for the ALIGN-ACS study in March 2026 to generate more data surrounding HeartBeam ECG’s application in heart attack detection, an area that could serve a 20 million-strong patient population in the US, as per data from the US Centers for Disease Control and Prevention (CDC).
